Induction of doxorubicin resistance in heterogeneous human colon tumor cells by N-methylformamide

L. A. Ferrari, S. F. Bliven, M. Wiemann, P. Calabresi, A. S. Glicksman, J. T. Leith

Research output: Contribution to journalArticle

Abstract

Two clonal subpopulations of cells (termed A and D) obtained originally from a heterogeneous human colon adenocarcinoma were studied in vitro with regard to possible modification of responsivity to graded doses of doxorubicin (ADM) after long-term growth in medium containing the differentiating agent N-methylformamide (NMF). Non-NMF-adapted clone A and D cells exhibited biphasic response curves after exposure to graded doses of ADM (0-1.4 μg/ml, 1 hour, 37° C). The inactivation slopes for the initial regions of the survival curves were 0.13 and 0.39 g/ml for clone A and D cells, respectively. NMF-adapted cells, however, exhibited decreased sensitivity to ADM killing as the inactivation slopes for the initial region of the survival curves increased to 0.26 and 0.59 g/ml for clone A and D cells, respectively. The final slopes of the biphasic response curves (doses above about 0.8 μg/ml) were not significantly different between clone A and clone D tumor cells in either the non-NMF- or NMF-treated conditions. These data on ADM responses after differentiation induction by NMF indicate that the combination of differentiation-inducing agents with certain chemotherapeutic agents may produce therapeutically undesirable effects and that preclinical data are necessary prior to implementation of possible combined-modality protocols.

Original languageEnglish
Pages (from-to)1177-1180
Number of pages4
JournalCancer Treatment Reports
Volume70
Issue number10
Publication statusPublished - 1986

Fingerprint

methylformamide
Doxorubicin
Colon
Clone Cells
Somatostatin-Secreting Cells
Neoplasms
Survival
Adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ferrari, L. A., Bliven, S. F., Wiemann, M., Calabresi, P., Glicksman, A. S., & Leith, J. T. (1986). Induction of doxorubicin resistance in heterogeneous human colon tumor cells by N-methylformamide. Cancer Treatment Reports, 70(10), 1177-1180.

Induction of doxorubicin resistance in heterogeneous human colon tumor cells by N-methylformamide. / Ferrari, L. A.; Bliven, S. F.; Wiemann, M.; Calabresi, P.; Glicksman, A. S.; Leith, J. T.

In: Cancer Treatment Reports, Vol. 70, No. 10, 1986, p. 1177-1180.

Research output: Contribution to journalArticle

Ferrari, LA, Bliven, SF, Wiemann, M, Calabresi, P, Glicksman, AS & Leith, JT 1986, 'Induction of doxorubicin resistance in heterogeneous human colon tumor cells by N-methylformamide', Cancer Treatment Reports, vol. 70, no. 10, pp. 1177-1180.
Ferrari, L. A. ; Bliven, S. F. ; Wiemann, M. ; Calabresi, P. ; Glicksman, A. S. ; Leith, J. T. / Induction of doxorubicin resistance in heterogeneous human colon tumor cells by N-methylformamide. In: Cancer Treatment Reports. 1986 ; Vol. 70, No. 10. pp. 1177-1180.
@article{8a77064fda904ce680871c05b7eeb154,
title = "Induction of doxorubicin resistance in heterogeneous human colon tumor cells by N-methylformamide",
abstract = "Two clonal subpopulations of cells (termed A and D) obtained originally from a heterogeneous human colon adenocarcinoma were studied in vitro with regard to possible modification of responsivity to graded doses of doxorubicin (ADM) after long-term growth in medium containing the differentiating agent N-methylformamide (NMF). Non-NMF-adapted clone A and D cells exhibited biphasic response curves after exposure to graded doses of ADM (0-1.4 μg/ml, 1 hour, 37° C). The inactivation slopes for the initial regions of the survival curves were 0.13 and 0.39 g/ml for clone A and D cells, respectively. NMF-adapted cells, however, exhibited decreased sensitivity to ADM killing as the inactivation slopes for the initial region of the survival curves increased to 0.26 and 0.59 g/ml for clone A and D cells, respectively. The final slopes of the biphasic response curves (doses above about 0.8 μg/ml) were not significantly different between clone A and clone D tumor cells in either the non-NMF- or NMF-treated conditions. These data on ADM responses after differentiation induction by NMF indicate that the combination of differentiation-inducing agents with certain chemotherapeutic agents may produce therapeutically undesirable effects and that preclinical data are necessary prior to implementation of possible combined-modality protocols.",
author = "Ferrari, {L. A.} and Bliven, {S. F.} and M. Wiemann and P. Calabresi and Glicksman, {A. S.} and Leith, {J. T.}",
year = "1986",
language = "English",
volume = "70",
pages = "1177--1180",
journal = "Cancer Treatment Reports",
issn = "0361-5960",
publisher = "U.S. National Cancer Institute",
number = "10",

}

TY - JOUR

T1 - Induction of doxorubicin resistance in heterogeneous human colon tumor cells by N-methylformamide

AU - Ferrari, L. A.

AU - Bliven, S. F.

AU - Wiemann, M.

AU - Calabresi, P.

AU - Glicksman, A. S.

AU - Leith, J. T.

PY - 1986

Y1 - 1986

N2 - Two clonal subpopulations of cells (termed A and D) obtained originally from a heterogeneous human colon adenocarcinoma were studied in vitro with regard to possible modification of responsivity to graded doses of doxorubicin (ADM) after long-term growth in medium containing the differentiating agent N-methylformamide (NMF). Non-NMF-adapted clone A and D cells exhibited biphasic response curves after exposure to graded doses of ADM (0-1.4 μg/ml, 1 hour, 37° C). The inactivation slopes for the initial regions of the survival curves were 0.13 and 0.39 g/ml for clone A and D cells, respectively. NMF-adapted cells, however, exhibited decreased sensitivity to ADM killing as the inactivation slopes for the initial region of the survival curves increased to 0.26 and 0.59 g/ml for clone A and D cells, respectively. The final slopes of the biphasic response curves (doses above about 0.8 μg/ml) were not significantly different between clone A and clone D tumor cells in either the non-NMF- or NMF-treated conditions. These data on ADM responses after differentiation induction by NMF indicate that the combination of differentiation-inducing agents with certain chemotherapeutic agents may produce therapeutically undesirable effects and that preclinical data are necessary prior to implementation of possible combined-modality protocols.

AB - Two clonal subpopulations of cells (termed A and D) obtained originally from a heterogeneous human colon adenocarcinoma were studied in vitro with regard to possible modification of responsivity to graded doses of doxorubicin (ADM) after long-term growth in medium containing the differentiating agent N-methylformamide (NMF). Non-NMF-adapted clone A and D cells exhibited biphasic response curves after exposure to graded doses of ADM (0-1.4 μg/ml, 1 hour, 37° C). The inactivation slopes for the initial regions of the survival curves were 0.13 and 0.39 g/ml for clone A and D cells, respectively. NMF-adapted cells, however, exhibited decreased sensitivity to ADM killing as the inactivation slopes for the initial region of the survival curves increased to 0.26 and 0.59 g/ml for clone A and D cells, respectively. The final slopes of the biphasic response curves (doses above about 0.8 μg/ml) were not significantly different between clone A and clone D tumor cells in either the non-NMF- or NMF-treated conditions. These data on ADM responses after differentiation induction by NMF indicate that the combination of differentiation-inducing agents with certain chemotherapeutic agents may produce therapeutically undesirable effects and that preclinical data are necessary prior to implementation of possible combined-modality protocols.

UR - http://www.scopus.com/inward/record.url?scp=0022505840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022505840&partnerID=8YFLogxK

M3 - Article

C2 - 3756940

AN - SCOPUS:0022505840

VL - 70

SP - 1177

EP - 1180

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 10

ER -